secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0000950170-23-020063
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Q1 net loss $96.5M ($1.33/sh); BEACON trial advancing, BEAM-201 on track
-----------------------------------------------------------------------------

- Net loss $96.5M ($1.33/sh) vs $69.2M ($1.01/sh) YoY; R&D spend up to $99.6M.
- Cash, equivalents and securities $1.1B; runway expected at least into 2025.
- BEACON trial sentinel cohort: first patient withdrawn (non-medical), 2 enrolled; full cohort expected in 2023.
- BEAM-201 Phase 1/2 for T-ALL/T-LL on track to dose first patient by mid-2023.
- Gopi Shanker appointed CSO; regulatory filings for BEAM-301 (late 2023/early 2024) and BEAM-302 (early 2024).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017023020063/0000950170-23-020063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017023020063/beam-20230510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer